trending Market Intelligence /marketintelligence/en/news-insights/trending/jnifwetbgNIAXnExbcvptg2 content esgSubNav
In This List

Ritter's lactose intolerance drug fails to reduce symptoms in late-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ritter's lactose intolerance drug fails to reduce symptoms in late-stage study

Ritter Pharmaceuticals Inc. said its lactose intolerance treatment RP-G28 failed to significantly reduce symptoms of the disorder compared to placebo in a late-stage study.

Lactose intolerance is a digestive disorder where patients are unable to produce enough of a certain enzyme required to digest lactose, the main carbohydrate in dairy products.

The Los Angeles-based pharmaceutical company was evaluating the drug for a reduction in symptoms of lactose intolerance, including abdominal pain, cramping, bloating and gas during the phase 3 trial. RP-G28 failed to perform better than the placebo.

Additionally, RP-G28 did not provide any meaningful treatment benefit as only 36.2% of patients who received the drug saw a reduction in their lactose intolerance, compared to 34.1% of the patients in the placebo group.

Ritter Pharmaceuticals CEO Andrew Ritter said the company is assessing a path forward, which may include alternative strategic options.

The company raised $6 million from a private placement of convertible preferred shares in November 2018 for the late-stage development of RP-G28. Ritter, which develops therapies for gastrointestinal diseases, received a noncompliance notice from the Nasdaq in December 2018 for failing to meet the exchange's $1 minimum bid price listing rule.